Comprehensive review of targeted therapy for colorectal cancer
作者机构：Division of Gastroenterology and HepatologyShanghai Institute of Digestive DiseaseState Key Laboratory for Oncogenes and Related GenesKey Laboratory of Gastroenterology&HepatologyMinistry of HealthRenji HospitalSchool of MedicineShanghai Jiao Tong University145 Middle Shandong Road200001 ShanghaiChina
出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)
年 卷 期：2020年第5卷第1期
页 面：2155-2184页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by grants from the National Natural Science Foundation of China(81421001 81530072 81830081 and 81772506)
主 题：Surgery drugs chemotherapy
摘 要：Colorectal cancer(CRC)is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in *** and chemotherapy have long been the first choices for cancer ***,the prognosis of CRC has never been satisfying,especially for patients with metastatic *** therapy is a new optional approach that has successfully prolonged overall survival for CRC *** successes with the anti-EGFR(epidermal growth factor receptor)agent cetuximab and the anti-angiogenesis agent bevacizumab,new agents blocking different critical pathways as well as immune checkpoints are emerging at an unprecedented *** worldwide are currently updating the recommended targeted drugs on the basis of the increasing number of high-quality clinical *** review provides an overview of existing CRC-targeted agents and their underlying mechanisms,as well as a discussion of their limitations and future trends.
维普期刊数据库